FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer By Ogkologos - September 19, 2025 376 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma January 8, 2021 Research shows one size doesn’t fit all for cervical screening in... May 17, 2021 6 highlights from our Black in Cancer conference October 31, 2022 4 Steps We Can All Take on World Cancer Day to... February 3, 2023 Load more HOT NEWS Treating the Whole Person: How Cancer Centers Are Addressing Social Needs Why consistent and funded cancer policies are key to improving cancer... Molecular Profiling with Targeted Panel Tests that Includes Fusion Detection Has... Tebentafusp Shows Promising Clinical Activity with an Acceptable Safety Profile in...
